Istraživanje leka protiv kovida 19 (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Istraživanje leka protiv kovida 19" in Serbian language version.

refsWebsite

Global rank Serbian rank

5web.archive.org

1^st place

4doi.org

2^nd place

4^th place

4nih.gov

4^th place

8^th place

3reuters.com

49^th place

103^rd place

3medscape.com

719^th place

468^th place

2rts.rs

1,751^st place

7^th place

2chinalawtranslate.com

low place

1bmj.com

1,226^th place

856^th place

1koreabiomed.com

low place

1pcpress.rs

low place

1,007^th place

1semanticscholar.org

11^th place

23^rd place

1mediterranee-infection.com

low place

1connexionfrance.com

low place

1techcrunch.com

187^th place

645^th place

1worldcat.org

5^th place

12^th place

1politika.rs

1,965^th place

11^th place

bmj.com

bestpractice.bmj.com

Beeching NJ, Fletcher TE, Fowler R (2020). „BMJ Best Practices: COVID-19” (PDF). BMJ. Архивирано из оригинала (PDF) 22. 02. 2020. г. Приступљено 18. 03. 2020.

chinalawtranslate.com

„Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition)”. China Law Translate. 4. 3. 2020.
„Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition)”. www.chinalawtranslate.com. 5. 3. 2020. Приступљено 18. 3. 2020.

connexionfrance.com

„French researcher posts successful Covid-19 drug trial”. www.connexionfrance.com. FRENCH NEWS. Архивирано из оригинала 17. 03. 2020. г. Приступљено 18. 3. 2020.

doi.org

Li G, De Clercq E (mart 2020). „Therapeutic options for the 2019 novel coronavirus (2019-nCoV)”. Nature Reviews. Drug Discovery. 19 (3): 149—150. PMID 32127666. doi:10.1038/d41573-020-00016-0 .
Lu, Hongzhou (2020). „Drug treatment options for the 2019-new coronavirus (2019-nCoV)”. Bioscience Trends. 14 (1): 69—71. PMID 31996494. S2CID 210945604. doi:10.5582/bst.2020.01020. .
Guaraldi, Giovanni (24. 6. 2020). „Tocilizumab in patients with severe COVID-19: a retrospective cohort study”. The Lancet, Rheumatology. 2 (8): e474—e484. PMC 7314456 . PMID 32835257. doi:10.1016/S2665-9913(20)30173-9.
Shah, Pallav L.; Orton, Christopher M.; Grinsztejn, Beatriz; Donaldson, Gavin C.; Crabtree Ramírez, Brenda; Tonkin, James; Santos, Breno R.; Cardoso, Sandra W.; Ritchie, Andrew I. (maj 2023). „Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care”. The Lancet. Respiratory Medicine. 11 (5): 415—424. ISSN 2213-2619. doi:10.1016/S2213-2600(22)00412-X.

koreabiomed.com

m.koreabiomed.com

Kwak, Sung (13. 2. 2020). „Physicians work out treatment guidelines for coronavirus”. m.koreabiomed.com 13. 2. 2020. Приступљено 18. 3. 2020.

mediterranee-infection.com

„1er résultats du traitement par Chloroquine du COVID-19 à l'IHU Méditerranée Infection”. www.mediterranee-infection.com. Архивирано из оригинала 18. 03. 2020. г. Приступљено 18. 3. 2020.

medscape.com

Hobbs, Brianne (2. 2. 2000). „Hydroxychloroquine: Possible COVID Drug Can Be Toxic to Retinas”. Medscape. Приступљено 2. 6. 2020.
„Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment”. www.medscape.com 17. 3. 2020. Архивирано из оригинала 28. 04. 2020. г. Приступљено 18. 3. 2020.
„Johnson & Johnson Says No Evidence HIV Drug Works Against Coronavirus”. www.medscape.com. Reuters Health Information, 17. 3. 2020. Архивирано из оригинала 18. 03. 2020. г. Приступљено 18. 3. 2020.

nih.gov

ncbi.nlm.nih.gov

Li G, De Clercq E (mart 2020). „Therapeutic options for the 2019 novel coronavirus (2019-nCoV)”. Nature Reviews. Drug Discovery. 19 (3): 149—150. PMID 32127666. doi:10.1038/d41573-020-00016-0 .
Lu, Hongzhou (2020). „Drug treatment options for the 2019-new coronavirus (2019-nCoV)”. Bioscience Trends. 14 (1): 69—71. PMID 31996494. S2CID 210945604. doi:10.5582/bst.2020.01020. .
Guaraldi, Giovanni (24. 6. 2020). „Tocilizumab in patients with severe COVID-19: a retrospective cohort study”. The Lancet, Rheumatology. 2 (8): e474—e484. PMC 7314456 . PMID 32835257. doi:10.1016/S2665-9913(20)30173-9.

pubmed.ncbi.nlm.nih.gov

Shah, Pallav L.; Orton, Christopher M.; Grinsztejn, Beatriz; Donaldson, Gavin C.; Crabtree Ramírez, Brenda; Tonkin, James; Santos, Breno R.; Cardoso, Sandra W.; Ritchie, Andrew I. (maj 2023). „Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care”. The Lancet. Respiratory Medicine. 11 (5): 415—424. ISSN 2213-2619. doi:10.1016/S2213-2600(22)00412-X.

pcpress.rs

„Američka FDA odobrila prvi lek za COVID-19”. www. pcpress.rs. PC press, 19. 3. 2020. 19. 3. 2020. Приступљено 20. 3. 2020.

politika.rs

„Američka agencija za hranu i lekove odobrila za hitnu upotrebu lečenje kovida antitelima”. Politika onlin, od 22.11.2020. Приступљено 22. 11. 2020.

reuters.com

„WHO: 'no known effective' treatments for new coronavirus”. Reuters, 5. 2. 2020. 5. 2. 2020. Приступљено 20. 3. 2020.
„WHO: 'no known effective' treatments for new coronavirus”. www.reuters.com. 5. 2. 2020. Приступљено 18. 3. 2020.
Steenhuysen, Julie (24. 1. 2020). „With Wuhan virus genetic code in hand, scientists begin work on a vaccine”. www.reuters.com. Reuters, 24. 1. 2020. Приступљено 18. 3. 2020.

rts.rs

„Koji lekovi se koriste u procesu lečenja koronavirusa”. RTS Beograd, 20. 3. 2020. Приступљено 20. 3. 2020.
„Počela prva testiranja vakcine protiv Kovida-19”. www.rts.rs. RTS Beograd 19. 3. 2020. Приступљено 19. 3. 2020.

semanticscholar.org

api.semanticscholar.org

Lu, Hongzhou (2020). „Drug treatment options for the 2019-new coronavirus (2019-nCoV)”. Bioscience Trends. 14 (1): 69—71. PMID 31996494. S2CID 210945604. doi:10.5582/bst.2020.01020. .

techcrunch.com

Etherington, Darrell (18. 3. 2020). „Japanese flu drug appears 'effective' in coronavirus treatment in Chinese clinical trials”. www. techcrunch.com 18. 3. 2020. Приступљено 20. 3. 2020.

web.archive.org

Beeching NJ, Fletcher TE, Fowler R (2020). „BMJ Best Practices: COVID-19” (PDF). BMJ. Архивирано из оригинала (PDF) 22. 02. 2020. г. Приступљено 18. 03. 2020.
„1er résultats du traitement par Chloroquine du COVID-19 à l'IHU Méditerranée Infection”. www.mediterranee-infection.com. Архивирано из оригинала 18. 03. 2020. г. Приступљено 18. 3. 2020.
„French researcher posts successful Covid-19 drug trial”. www.connexionfrance.com. FRENCH NEWS. Архивирано из оригинала 17. 03. 2020. г. Приступљено 18. 3. 2020.
„Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment”. www.medscape.com 17. 3. 2020. Архивирано из оригинала 28. 04. 2020. г. Приступљено 18. 3. 2020.
„Johnson & Johnson Says No Evidence HIV Drug Works Against Coronavirus”. www.medscape.com. Reuters Health Information, 17. 3. 2020. Архивирано из оригинала 18. 03. 2020. г. Приступљено 18. 3. 2020.

worldcat.org

Shah, Pallav L.; Orton, Christopher M.; Grinsztejn, Beatriz; Donaldson, Gavin C.; Crabtree Ramírez, Brenda; Tonkin, James; Santos, Breno R.; Cardoso, Sandra W.; Ritchie, Andrew I. (maj 2023). „Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care”. The Lancet. Respiratory Medicine. 11 (5): 415—424. ISSN 2213-2619. doi:10.1016/S2213-2600(22)00412-X.